


PRODUCT: CFI-400945

ALTERNATE NAME: (1R,2S)-2-(3-((E)-4-(((2S,6R)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one

CATALOG #: B1287-5,25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₃₃H₃₄N₄O₃

MOLECULAR WEIGHT: 534.65

CAS NUMBER: 1338806-76-0

APPEARANCE: Crystalline solid

SOLUBILITY: DMSO

PURITY: ≥98% by HPLC

STORAGE: Store at -20°C. Protect from air and light.

DESCRIPTION: CFI-400945 is a potent, ATP-competitive inhibitor of PLK4 (Polo-like kinase 4) (K_i = 0.2 nM). Displays anticancer properties. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells.

REFERENCES: Yu, B., *et al.* (2015). *Eur. J. Med. Chem.* **95**, 35-40.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

BI-6727 (Cat. No. 2222-1,5)

BI-2536 (Cat. No. 2370-5, 25)

CIF-400945 (Cat. No. B1287-5,25)

GSK461364 (Cat. No. 2287-5, 25)

Rigosertib (Cat. No. 9482-5,25)

Ro3280 (Cat. No. B1175-5,25)

SBE13 hydrochloride (Cat. No. 2847-10, 50)

Wortmannin (Cat. No. 1670-1)

USAGE: **FOR RESEARCH CH USE ONLY! Not to be used in humans**